INTELLIGENT BIO SOLUTIONS INC. (INBS)
INTELLIGENT BIO SOLUTIONS INC. (INBS)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Provision for credit losses | NaN | NaN | 73 | 546 |
| Net loss | -2,869,640 | -2,686,613 | -2,994,992 | -10,604,886 |
| Depreciation and amortization | NaN | 327,367 | 257,907 | 970,117 |
| Impairment of long-lived assets | NaN | 243,456 | 45,471 | 243,632 |
| Depreciation and amortization | 875,667 | NaN | NaN | NaN |
| Impairment of long-lived assets | 32,347 | NaN | 261,780 | 220,062 |
| Inventory write-downs | 37,311 | NaN | NaN | 0 |
| Provision for product warranties | 29,355 | NaN | NaN | NaN |
| Stock-based compensation | 24,204 | 61,575 | 12,000 | 238,045 |
| Non-cash adjustment on r&d expenditure claims | 2,476 | -127,108 | NaN | 137,696 |
| Non-cash other operating activities | 137,827 | 115,509 | -147,842 | -113,645 |
| Accounts receivable | 421,700 | -261,166 | 123,209 | 164,910 |
| Non-cash loss on foreign currency translation, net | NaN | NaN | NaN | 0 |
| Inventories | 7,223 | -37,931 | -7,038 | -142,322 |
| Research and development tax incentive receivable | 63,428 | -418,890 | 189,654 | 209,076 |
| Other current assets | 362,957 | -8,049 | -338,794 | 329,404 |
| Accounts payable and accrued expenses | -722,398 | 45,450 | -567,109 | 2,577,151 |
| Grant receivable / deferred grant income | NaN | NaN | NaN | 2,486,668 |
| Long-term employee benefit liabilities | -66,230 | 6,885 | 15,120 | 21,306 |
| Fair value gain on revaluation of holdback series c preferred stock | NaN | NaN | NaN | 0 |
| Operating lease liabilities | -63,158 | -41,417 | -57,886 | -271,499 |
| Net cash used in operating activities | -4,330,574 | -1,567,515 | -2,846,825 | -9,677,313 |
| Proceeds from sale of assets held for sale | 0 | 40,158 | NaN | NaN |
| Purchase of property and equipment | -12,902 | 68,232 | 70,401 | 231,838 |
| Net cash used in investing activities | 12,902 | -28,074 | -70,401 | -231,838 |
| Proceeds from exercise of warrants, net of issuance costs | NaN | NaN | NaN | 7,939 |
| Proceeds from private placement, net of issuance costs | NaN | NaN | NaN | 0 |
| Proceeds from issuance of common stock, net of issuance costs | 489,046 | 674,651 | 224,534 | 4,589,866 |
| Proceeds from issuance of common stock for warrants exercised, net of issuance costs | 9,949,855 | 0 | 3,333,631 | NaN |
| Net cash provided by financing activities | 10,438,901 | 674,651 | 3,558,165 | 4,597,805 |
| Effect of foreign exchange rates on cash and cash equivalents | 604 | 1,204 | -743 | 27,157 |
| Net increase (decrease) in cash and cash equivalents | 6,121,833 | -919,734 | 640,196 | -5,284,189 |
| Cash and cash equivalents, beginning of period | 740,371 | 1,660,105 | 1,019,909 | NaN |
| Cash and cash equivalents, end of the period | 6,862,204 | 740,371 | 1,660,105 | NaN |